Word: hiv
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...most important - lives are saved. In the past year and a half, (RED) has generated $100 million for the Global Fund to Fight AIDS, Tuberculosis and Malaria, helping put nearly 80,000 people in poor countries on lifesaving drugs and helping more than 1.6 million get tested for HIV. That's creative capitalism at work...
...July 17, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, scrapped plans for a large clinical trial of the government's most advanced HIV vaccine candidate to date. The vaccine, a two-shot injection, was designed to fight HIV infection a new way - by activating the body's cell-based immune responses rather than by relying on antibodies to HIV...
...decision did not come as a complete surprise, since a similar and widely publicized vaccine developed by Merck failed to prevent infection or control HIV replication in a trial last year. At issue is the fact that researchers still don't know exactly how the body defends against HIV. Without critical knowledge of the precise immune factors, or correlates, that prevent infection, testing any vaccine candidate that functions by triggering immune defenses would be guesswork. That's why, Fauci says, he rejected the proposal to do a large trial, involving thousands of patients and numerous immune correlates. "What I will...
...trial that Fauci canceled last week was already a slimmed down version of the original 8,500-person study that government health officials had planned - until the Merck vaccine failed last fall. In a trial of 3,000 volunteers, Merck's vaccine appeared to increase risk of HIV infection, a phenomenon that researchers later attributed to the vaccine's delivery system - pieces of HIV were piggybacked onto a common cold virus and ferried to the body's immune cells. It turned out that the people who received the vaccine and who ended up with the highest rates of HIV infection...
...says, the best way to answer that question is by narrowing the focus of a vaccine study to see if it can do one thing: reduce the viral load in someone infected with HIV. If a vaccine can do that, it's worth looking at more closely to figure out how it does it. "Scaling back the trial to look at a single endpoint is a concept that a number of us have championed," agrees Wayne Koff, senior vice president of research and development at the International AIDS Vaccine Initiative...